Hypoxia is a key component of the tumor microenvironment and represents a well-documented source of therapeutic failure in clinical oncology. Recent work has provided support for the idea that non-coding RNAs, and in particular, microRNAs, may play important roles in the adaptive response to low oxygen in tumors. Specifically, all published studies agree that the induction of microRNA-210 (miR-210) is a consistent feature of the hypoxic response in both normal and malignant cells. miR-210 is a robust target of hypoxia-inducible factors, and its overexpression has been detected in a variety of diseases with a hypoxic component, including most solid tumors. High levels of miR-210 have been linked to an in vivo hypoxic signature and to adverse prognosis in breast and pancreatic cancer patients. A wide variety of miR-210 targets have been identified, pointing to roles in mitochondrial metabolism, angiogenesis, DNA damage response, apoptosis, and cell survival. Such targets are suspected to affect the development of tumors in multiple ways; therefore, an increased knowledge about miR-210's functions may lead to novel diagnostic and therapeutic approaches in cancer.
Introduction
Hypoxia, the condition of insufficient oxygen supply to tissues, results from a reduction in oxygen availability, inadequate oxygen transport, or the inability of the tissues to utilize oxygen. In normal tissues, high-altitude exposure, anemia, and drugs can induce hypoxia-responsive pathways in the body. Cells react to hypoxia, in part, via a transcriptional program that is largely orchestrated by the core component of the hypoxia-sensing machinery, the hypoxia-inducible factors (HIFs) [1] [2] [3] . HIFs are heterodimers consisting of an oxygen-sensitive alpha subunit (HIFa) and a constitutively active beta subunit (HIF1b, also called aryl hydrocarbon receptor nuclear translocator, ARNT).
Among the three homologous HIFa genes-HIF1a, HIF2a, and HIF3a-the functions of HIF1a and HIF2a are the best characterized. HIF1a is ubiquitously expressed in essentially all tissue types, while HIF2a expression is more tissue-specific [4] .
Under normoxic conditions, HIFa is hydroxylated by prolyl-4-hydroxylases (PHDs), targeting it for proteasome destruction mediated by the von Hippel Lindau (VHL) protein, a subunit of an E3 ubiquitin ligase [5, 6] . Under hypoxic conditions, the activity of PHDs decreases and HIFa is stabilized and forms a dimer with HIF1b. The HIFa/HIF1b dimer is then translocated to the nucleus and binds specifically to the promoters of hundreds of genes involved in adaptation and protection against low oxygen conditions, including those genes involved in energy metabolism, cell survival and proliferation, angiogenesis, adhesion, and motility [7] .
Hypoxia is also a hallmark of all solid tumors, where cancer cells shift their energy production from the tricarboxylic acid (TCA) cycle to glycolysis [8] . Compared with normal tissues, in which the distance between blood vessels is carefully regulated, the vasculature of solid tumors is comparatively disorganized, with many irregularities and abnormalities, including blood vessels with 'blind ends' and temporary occlusions and a wide variation in the distance between the blood vessels that carry oxygen and other vital nutrients to surrounding tissues [9] . Furthermore, in tumors the growth of malignant cells is unregulated, and some cells or regions can outgrow their blood supply, leading to deficiencies in the perfusion of oxygen and nutrients.
The abnormalities in tumor vasculature and the exaggerated intercapillary spacing lead to hypoxic microenvironments that do not exist in normal tissues [10] . This unique tumor microenvironment inhibits access of traditional anti-cancer agents to hypoxic tumor cells [11] . Tumor cells Acta Biochim Biophys Sin 2014, 46: 220 -232 | ª The Author 2014. Published by ABBS Editorial Office in association with Oxford University Press on behalf of the Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences. DOI: 10.1093/abbs/gmt141. Advance Access Publication 6 January 2014 in these hypoxic zones are also relatively quiescent, which renders them refractory to most cancer chemotherapies that typically target the rapidly proliferating cells [12] .
As a response to the presence of tumor cells, a plethora of host immune cells are usually recruited to the tumor microenvironment [13] . The exact role of these immune cells is highly context-dependent: they can either promote tumor progression or eliminate tumor cells [14] . Hypoxia is known to be a critical regulator of immune cell function [15] . However, tumor cells can usually utilize the hypoxic microenvironment to evade the host immune system by promoting immune tolerance and escaping immune surveillance [16, 17] , contributing to tumor initiation, development, and progression.
An intratumor hypoxic state can also lead to the upregulation of genes that confer resistance to chemotherapeutic drugs and radiotherapy, as well as genes that play a major role in initiating angiogenesis [9] . In addition, tumor-associated hypoxia tends to select cells that possess a profoundly malignant, metastatic phenotype [18 -21] , which ultimately contributes to treatment relapse. As a consequence, tumor hypoxia has been associated with poor clinical outcome and is a negative prognostic indicator, independent of tumor size, stage, histology, grade, and nodal status [12] . Thus, tumor hypoxia represents a compelling target for therapeutic intervention, and better understanding of hypoxia gene regulation will provide novel targets for cancer treatment [22] .
Although it is well known that there are hundreds, if not thousands, of genes involved in adaptation and protection against low oxygen conditions, in this review, we will focus on the non-protein-coding RNAs of the transcriptome that are responsive to hypoxic conditions, many of which were only discovered recently.
Non-coding RNAs-Critical Regulators of Gene Function
Following the completion of the Human Genome Project, it is a surprise that the protein-coding sequence only counts for 1.1% of the entire human genome [23] . The rest is called genomic 'dark matter', 'junk DNA', or 'gene desert', without any coding capacity or obvious function. Nonetheless, it is estimated that at least 80% of the human genome consists of functional sequences, either transcribing non-coding RNAs (ncRNAs) or being involved in chromatin-associated regulatory function [24] . Recent evidence further supports this conclusion by demonstrating that only 5% of transcription initiation complexes in the human K562 cell genome are associated with messenger RNA (mRNA) genes [25] . Given the pressure of natural selection during the evolution that has shaped the human genome, it is unlikely that these non-coding transcripts are conserved merely as the 'background noises' of protein-coding gene transcription.
In the last decade, because of the rapid development of microarray and next-generation sequencing technologies, the dark matter of the human genome has slowly been revealed to encode tens of thousands of ncRNAs, including ribosomal RNAs, small nucleolar RNAs, small nuclear RNAs, transfer RNAs, small interfering RNAs, piwi-associated RNAs, microRNAs (miRNAs), unusually small RNAs, enhancer region RNAs, and long non-coding RNAs (lncRNAs). Despite being unable to be translated into proteins, many of these are known or suspected to regulate biological functions in almost any imaginable fashion. Among ncRNAs, miRNAs and lncRNAs have been demonstrated to be regulated under hypoxic conditions. Thus, our discussion will focus on miRNAs and lncRNAs here. lncRNAs lncRNA is a loose term for ncRNA molecules that are longer than 200 nucleotides in length [26] . XIST, a master regulator of X chromosome inactivation [27] , may be the best known lncRNA. XIST is transcribed from the X chromosome and serves as a centre to initiate and spread X inactivation in cis [28] . The discovery of the HOTAIR lncRNA demonstrated for the first time that lncRNA can function in trans [29] . It is generally believed that transacting lncRNAs function as a scaffold to facilitate the formation of ribonucleoprotein (RNP) complexes with numerous chromatin regulators and transcription factors, thus regulating target gene expression [26] .
Hypoxic regulation of lncRNA expression. Despite recent rapid progress in lncRNA study, the role of hypoxia in regulating lncRNA expression has not been extensively investigated, with only a few examples in this category. H19, a well-known maternally imprinted lncRNA [30] , is robustly induced under hypoxic conditions. Interestingly, H19 is essential for tumorigenesis in hepatocellular and bladder carcinomas [31] , which is consistent with the general role of hypoxia in promoting tumor progression.
In addition to H19, transcripts from ultraconserved regions were recently found to be induced by hypoxia [32] . This class of lncRNAs, also termed 'hypoxia-induced non-coding ultraconserved transcripts' (HINCUTs), may play important roles in mediating functions in the hypoxia response pathways. One of the HINCUTs, HINCUT-1 has been demonstrated to regulate cell proliferation and optimal O-GlcNAcylation of proteins specifically under hypoxic conditions.
The expression of lncRNAs can also be repressed by hypoxia. lncRNA-LET, a lncRNA generally downregulated in hepatocellular carcinomas, colorectal cancers, and squamous-cell lung carcinomas, has been found to be repressed, under 1% oxygen, through histone deacetylation in its promoter region, mediated by hypoxia-induced HDAC3 expression [33] . More hypoxia-responsive lncRNAs are expected to be identified due to the rapidity of technical miR-210 in hypoxic response advancement, especially with the declining cost of nextgeneration sequencing technologies. miRNAs miRNAs are small, single-stranded ncRNA molecules ( 22 nucleotides in length) that regulate gene expression by inhibiting mRNA translation or by facilitating cleavage of the target mRNA [34] . Our understanding of miRNA biology began rather slowly; the first miRNA, lin-4, was discovered in Caenorhabditis elegans in 1993 [35, 36] , but the second miRNA, let-7, was not discovered until 2000 [37] . The finding that let-7 is well conserved in a wide range of animal species [38] stimulated an explosion in miRNA discovery that is still ongoing today. More than 2000 miRNAs have been identified in the human genome to date, and it has been estimated that 30% of protein-encoding genes are regulated by miRNAs [39] . Actually, we propose that all proteincoding genes are subject to miRNA regulation as long as they maintain a 3 0 -untranslated region (3 0 UTR) sequence. miRNAs are now widely recognized as important regulators in developmental, physiological, and pathological settings, including cell growth, differentiation, and metabolism, viral infection, and tumorigenesis [40] . miRNA biogenesis. Genes encoding miRNAs are initially transcribed by RNA polymerase II as part of much longer primary transcripts ( pri-miRNAs) [41] , typically containing a cap structure and poly(A) tails [42] . In the second step, pri-miRNAs are processed by the nuclear RNase III Drosha, leading to 70-nucleotide (approximately), hairpin-shaped intermediaries, termed precursor miRNAs ( pre-miRNAs). Pre-miRNAs are subsequently exported out of the nucleus by exportin-5 and cleaved by the cytoplasmic RNase III Dicer into short miRNA duplexes. One strand of this shortlived duplex is degraded, while the other strand is retained as mature miRNA and incorporated into the RNA-induced silencing complex (RISC) [43] , an RNA-protein complex with subunits from the Argonaute family.
Mechanisms of miRNA function. Mature miRNA guides the RISC to recognize its target mRNA on the basis of sequence complementarity, most importantly between the 'seed region' of mature miRNAs, nucleotides 2-8, and the 3 0 UTRs of their target genes, which generally leads to translation inhibition and/or mRNA degradation [44, 45] . Because, usually, a perfect sequence complementarity is only required between the seed region of a miRNA and the 3 0 UTR of its target mRNA, theoretically, a single miRNA can regulate multiple mRNAs, often hundreds, and the 3 0 UTR of an mRNA may contain several miRNA recognition sequences in its 3 0 UTR. This relative lack of specificity poses significant challenges for elucidating the mechanism of miRNA action, in particular, in identifying biologically meaningful miRNA targets.
Besides functioning through the RISC, non-canonical miRNA function has also been identified. miR-328 has been shown to act as a decoy in chronic myelogenous leukemia to bind translational regulator poly(rC)-binding protein hnRNP E2 to protect CEBPA mRNA from hnRNP E2-mediated translational inhibition [46] . In sarcoma, miR-29 can act as a decoy to bind the RNA-binding protein HuR to save the tumor suppressor A20 mRNA from degradation by HuR [47] . Secreted miRNAs can also function as ligands to bind to receptors of the Toll-like receptor family [48] , suggesting that miRNA may function as a 'hormone' in paracrine or endocrine signaling, which may provide a functional explanation for the presence of large amounts of cell-free miRNA in human circulation.
Recently, the classical view of miRNA regulating target genes by binding to their 3 0 UTRs has also been challenged. miRNAs can not only bind to the 5 0 UTRs of their target genes [49] , but also to the gene coding region [50] . Thus, miRNAs can bind to virtually any region in their target transcripts, greatly expanding the number of their potential targets.
Surprisingly, miRNAs have also been found to activate target gene transcription or enhance protein translation [51] [52] [53] [54] , suggesting miRNAs are versatile players in regulating cellular functions. Thus, the 'competing endogenous RNA' theory provides an attractive model for the complex miRNAmRNA and miRNA-miRNA interactions [55] .
miRNA expression in cancer. Aberrant miRNA expression patterns have been demonstrated in all cancers. Interestingly, different cancer types also tend to exhibit specific signatures of dysregulated miRNAs [56, 57] , including cancers of the colon [58] , breast [59] , brain [60] , liver [61] , and lung [62] . While the mechanisms underlying the specific profile shifts in these tumors have long remained elusive, recent discoveries regarding miRNA responses to microenvironment stress and oncogenic alteration have provided useful clues. Since tumor hypoxia is one of the most important microenvironmental factors during tumor initiation and development, not surprisingly, miRNAs have been found to regulate many aspects of cellular hypoxic response [63] [64] [65] [66] [67] [68] [69] .
In the next section, we will summarize the current understanding of miRNA involvement in cellular hypoxic response, with a focus on miR-210; we will discuss the challenges we face in elucidating their biological functions and speculate on the opportunities for cancer diagnosis and treatment presented by these miRNAs.
Hypoxia-Regulated miRNAs-the New Regulator in the Hypoxic Response Pathway
In the past several years, genome-wide miRNA profiling has identified many hypoxia-regulated miRNAs in a variety of miR-210 in hypoxic response cells with diverse genetic background, such as miR-20a, -21, -24, -103, -107, -210, -424, and let-7 [65, 66, [70] [71] [72] [73] . However, many of these miRNAs are only reported in limited number of studies, indicating a tissue-or cell typespecific hypoxic response of miRNA expression. miR-210, on the other hand, stands out as being the only miRNA consistently and robustly induced under hypoxic conditions in essentially all experimental systems, in vivo or in vitro, in cancer cells or in normal cells under a physiological hypoxic condition [74] , suggesting that miR-210 is the dominant responder, in the miRNA realm, to hypoxic stress.
In this review, discussion will be focused on miR-210's function in the context of cancer biology.
miR-210-a marker for tumor hypoxia Despite being identified as a HIF1a target in a majority of experiments [65, 67, 75, 76] , miR-210 has also been shown to be regulated by HIF2a [77] . As is the case with many classic HIF1a-regulated genes, HIF1a binds directly to a hypoxia-responsive element (HRE) on the proximal miR-210 promoter [65] . When the miR-210 core promoter is compared across species, this HRE site is highly conserved, indicating the importance of hypoxia in regulating miR-210 expression in these species. Consistent with this observation, induction of mouse miR-210 under hypoxia is dependent on Hif1a [76] . Recently, this highly conserved HRE was confirmed to be the functional HRE that is responsible for the robust induction of mouse miR-210 expression under hypoxic conditions [78] . Other than the HIFs, reports of regulation of miR-210 expression by other transcription factors have been sparse. Recently, convincing evidence is provided that Oct2 can induce miR-210 expression to regulate B-cell function and inhibit autoantibody production [79] . Interestingly, in silico analysis of the miR-210 promoter sequence suggests the presence of several highly conserved transcription factor binding sites in the close vicinity of miR-210's HRE site, such as E2F1, Oct4, and PPARg, suggesting that miR-210 expression may be regulated by these factors in a tissue-or cell type-specific manner that has yet been extensively explored.
It is well-known that the stromal microenvironment is critical for tumor development and response to therapy [80] . As a consequence of the uncontrolled cell proliferation and disorganized and dysfunctional tumor vasculature [9] , the microenvironment of solid tumor cells is usually hypoxic, which is especially true for pancreatic cancer. Because of excessive desmoplastic reaction, oxygen perfusion from blood vessels to pancreatic cancer cells is severely attenuated, leading to a highly hypoxic microenvironment [81] . Thus, hypoxia plays an important role in regulating the interaction between the pancreatic tumor cells and stellate cells to promote fibrosis and angiogenesis [82, 83] . In support of this, miR-210 was recently identified as a mediator of tumor -stroma interaction in a co-culture experiment of pancreatic tumor cells and stellate cells [84] . The presence of the pancreatic stellate cells can lead to elevated miR-210 expression in pancreatic tumor cells to enhance their epithelialmesenchymal transition phenotypes [84] . In addition, we have also discovered that miR-210 expression is correlated with a gene expression signature of hypoxia in primary head and neck tumors [65] , further suggesting that miR-210 expression may reflect the in vivo hypoxic microenvironment in which tumor cells reside.
miR-210 is upregulated in most solid tumors, and its levels correlate with a negative clinical outcome [64, [85] [86] [87] [88] [89] . One particular disease that associates closely with the HIF pathway is clear cell renal cell carcinoma (ccRCC), which is commonly associated with the loss of chromosome 3, that harbors the tumor suppressor gene VHL [90, 91] . Mutation and loss of heterozygosity of the VHL gene have been found in 57% and 98%, respectively, of sporadic RCC cases [92] . The VHL gene encodes pVHL, a subunit of an E3 ubiquitin ligase complex that targets the hydroxylated, oxygen-sensitive HIF1a and HIF2a for ubiquitination and subsequent degradation [5, 6] . More importantly, inhibiting HIF could significantly reduce the ability of renal carcinoma cells to form tumors in mouse xenograft models [93, 94] , suggesting that upregulation of the hypoxia response pathway in VHLdeficient cells plays a critical role in RCC tumorigenesis.
Given its robust induction by HIF1a, it is not surprising that miR-210 is overexpressed in ccRCC [95 -97] . More interestingly, significantly elevated circulating miR-210 levels have been found in ccRCC patients relative to healthy controls [98] . Significant levels of circulating miR-210 have also been reported in other tumor types [99] [100] [101] , especially in pancreatic cancer [99, 101] , which is known for the presence of highly hypoxic tumors [81] , suggesting that circulating miR-210 could serve as a specific biomarker for non-invasive detection of highly hypoxic cancers.
miR-210 target identification -current status and challenges
To fully understand the function of a miRNA, it is essential to identify its biologically relevant target genes. However, the search for such targets remains a major challenge in miRNA research. The most frequently employed approach in identifying miRNA targets is through computational prediction, which is based on the complementarity of the target gene's 3 0 UTR sequence and the seed region sequence of a miRNA [102] . Many algorithms, such as miRanda [103] , TargetScan [104] , Pictar [105] , PITA [106] , MicroCosm [107] , and DIANALab [108] , are readily available online at no cost. However, since the miRNA seed region only consists of six or seven nucleotides, false-positive prediction is a major limitation of this approach. Any given miRNA may be predicted to regulate hundreds, if not thousands, of target miR-210 in hypoxic response genes. When the search is extended to the 5 0 UTR, the coding region, or even to 'seedless' targets [109, 110] , the number of potential miRNA targets is expected to be even higher. It is also becoming increasingly apparent that 'seed' binding is not always sufficient, as other features of the surrounding sequences can affect binding efficacy [39] . Furthermore, the lists of candidates generated by these different algorithms usually exhibit very limited overlap, exemplified by a proteomic study to compare the accuracy of different computational programs on predicting miR-223 targets [111] .
Computational prediction of miR-210, using the aforementioned algorithms, generates a long list of potential targets with a variety of biological functions, including genes involved in proliferation, DNA repair, chromatin remodeling, metabolism, and cell migration [67] [68] [69] 76, [112] [113] [114] [115] . Interestingly, two widely used algorithms, PicTar and TargetScan, predict relatively few targets for human miR-210, but many experimentally validated targets are not predicted by any of these programs. Such difficulties prompted the use of integrated bioinformatics and experimental approaches in order to identify authentic miR-210 targets.
A major mechanism used by miRNAs to downregulate target genes is the degradation of their mRNAs [116, 117] , which can be reliably and robustly detected by microarray or whole transcriptome RNA sequencing (RNA-Seq). When an miRNA of interest is overexpressed or knocked-down in cells, the combination of computational prediction and identification of genes with corresponding transcript changes can be used to delineate putative miRNA targets. This strategy is straightforward and has been quite successful in identifying miR-210 targets [77, 118] .
However, a caveat to this approach is that it may miss authentic miRNA targets because miRNAs frequently regulate target genes by inhibiting their protein translation without changing their mRNA expression [119] . Theoretically, sensitive proteomic profiling would allow unbiased and comprehensive identification of miRNA targets following perturbing cellular miRNA expression by miRNA knockdown or overexpression. However, lack of sufficient sensitivity and the requirement of sophisticated and expensive equipment in proteomic profiling limit the application of this strategy.
A promising approach to identifying miRNA targets has recently emerged from mechanistic studies of miRNA action. Because miRNAs recruit the mRNAs of their target genes through the RISC, a protein-RNA complex, of which the Argonaute family of proteins, especially Argonaute 2, is an essential component [120] , Argonaute protein immunoprecipitation (miRNP-IP), followed by microarray or RNA-Seq, can identify targets that directly interact with miRNAs [121] , thus minimizing the number of non-specific targets and secondary effects. miRNP-IP has been successfully used to identify miR-210 targets [65, 122] .
In our study, we used a combination of computational prediction, transcriptomic, and miRNP-IP approaches [65] . By comparing mRNAs enriched in the RISC after MCF10A cells were exposed to 0.5% oxygen for 24 h or treated under normoxia, we identified more than 200 mRNAs that are enriched in cells under 0.5% oxygen, with 50 of these predicted as direct miR-210 targets. Eventually, three out of five randomly selected genes from the 50-gene list were confirmed as bona fide miR-210 targets by functional assays, exemplifying the power of the miRNP-IP approach.
With the lowering cost of RNA-Seq, the combination of more accurate computational algorithms and miRNP-IP will provide more complete and accurate identification of physiologically relevant miR-210 targets. Table 1 is a summary of experimentally identified miR-210 targets with potential functions in cancer. The function of some of these genes will be further discussed below.
miR-210 regulation of the cell cycle
Hypoxia has a profound impact on cell proliferation. Recently, miR-210 has been found to play an important role in mediating HIF1a-regulated cell cycle progression. One of the best characterized miR-210 targets for cell cycle control is E2F3, a promoter of the G1/S transition [134, 135] . E2F3 was initially reported as a miR-210 target in ovarian cancer miR-210 in hypoxic response [69] . Later, it was confirmed as a miR-210 target in several independent studies, including studies of ccRCC [128] , keratinocytes and a murine model of ischemic wounds [136] , and HEK293 cells [122] . However, the relative contribution of E2F3 to tumor cell cycle alterations under a hypoxic microenvironment still remains largely unknown. In addition to E2F3, fibroblast growth factor receptor-like 1 (FGFRL1) was also identified as a miR-210 target involved in cell cycle control [129] , consistent with our earlier finding that FGFRL1 is one of the most robustly repressed miR-210 targets [65] . Decreased miR-210 expression in esophageal squamous cell carcinomas released FGFRL1 from miR-210 repression, leading to accelerated cell cycle progression. In contrast, overexpressed miR-210 induces cell cycle arrest in G1/G0 and G2/M phases [129] . Recent work has suggested that miR-210 may have a much broader effect on cell cycle regulation, as its expression was correlated with the downregulation of a group of mitosis-related genes, including Plk1, Cdc25B, Cyclin F, Bub1B, and Fam83D [130] .
As is often seen in biological systems, genes may display dramatically different functions in a context-dependent manner. In contrast to its role in reducing cell cycle progression by targeting E2F3 and FGFRL1, miR-210 has also been demonstrated to promote cell cycle progression by downregulating MNT [77] , one of the top miR-210 targets identified in our miRNP-IP experiment [65] . MNT is a member of the MYC/MAX/MAD network, with a basic Helix-Loop-Helixzipper domain and represses MYC target genes by binding the E box DNA sequence (CANNTG) after forming heterodimers with MAX [137, 138] . Interestingly, E2F3 is also a target of MYC [139] , suggesting that miR-210 may be able to positively or negatively regulate MYC activity by targeting MNT or E2F3. Because HIF1a regulates cell proliferation and metabolism under hypoxia by interacting with c-MYC [140] , miR-210 may serve as a rheostat to fine tune the net output of the c-MYC signaling pathway under hypoxic conditions to regulate cell cycle progression.
Despite the strong mechanistic evidence of the miR-210's role in regulating cell cycle progression, we and other groups did not observe a marked change in the cell growth in the head & neck or the pancreatic cancer cell lines following miR-210 overexpression [65, 141] , indicating that the mechanism of the miR-210's impact on cell proliferation is more complex than we have yet understood. Thus, more research is warranted to elucidate miR-210 function on cell cycle regulation.
miR-210 regulates angiogenesis
Tumor hypoxia has an intricate connection with angiogenesis [9] . Numerous pro-angiogenic factors are upregulated in cells as a response to a hypoxic microenvironment [10] , with vascular endothelial growth factor (VEGF) as the best example [142, 143] . Interestingly, miR-210 expression was found to correlate closely with VEGF expression, hypoxia, and angiogenesis in breast cancer patients [88] , indicating a possible role for miR-210 in tumor angiogenesis. However, given its robust induction under hypoxic conditions, this correlation alone is not sufficient to determine whether miR-210 functionally regulates breast cancer angiogenesis.
In two independent studies, forced miR-210 expression in normoxic human umbilical vein endothelial cells (HUVECs) stimulates the formation of capillary-like structures, as well as VEGF-induced cell migration, while inhibiting miR-210 antagonizes both tubulogenesis and VEGF-mediated endothelial chemotaxis [68, 144] , supporting a causal role for miR-210 in promoting angiogenesis. Despite no miR-210 target having been discovered in one of these studies [144] , the receptor tyrosine kinase ligand Ephrin-A3 (EFNA3) was identified as a miR-210 target for promoting the angiogenic properties of VEGF [68] , consistent with the fact that the function of ephrin ligands and their receptors are important in the development of the cardiovascular system and in vascular remodeling [145] .
Paradoxically, despite its being one of the most consistent miR-210 target genes [65, 68, 122, 146, 147] , EFNA3 expression is highly induced in post-ischemic mouse hippocampus or under hypoxic conditions [112] . Thus, we speculate that EFNA3 mRNA may possess an independent non-coding function under hypoxic conditions and that miR-210 is a mechanism to limit EFNA3 protein production in the cells.
Ptp1b, a protein tyrosine phosphatase, was identified as another miR-210 target that promotes angiogenesis and inhibits cellular apoptosis following mouse myocardial infarction [126] . It has been previously shown that PTP1B can negatively regulate the activation of a VEGF receptor, VEGFR2, by binding to it and can stabilize cell-cell adhesions through reducing tyrosine phosphorylation of vascular endothelial cadherin in endothelial cells [148] . Thus, by inhibiting Ptp1b and Efna3, both negative regulators of angiogenesis, miR-210 could promote angiogenesis. This mechanism is further supported by recent findings that the overexpression of miR-210 in HUVECs can enhance VEGF and VEGFR2 expression to augment angiogenesis despite no miR-210 targets having been identified in the study [149] . Interestingly, a recent study also suggested a positive feedback mechanism from VEGF to miR-210, in which umbilical cord blood CD34 þ cells, expanded in a VEGFcontaining medium, had a significant upregulation of miR-210 expression, and when these cells were transplanted into ischemic mouse hind limbs, the tissue perfusion and capillary density were significantly improved, while a miR-210 inhibitor abolished such an effect [150] . Aside from the VEGF axis, miR-210 can also promote angiogenesis by upregulating Notch1 and inducing endothelial cells to migrate and form capillary-like structures on Matrigel [144] .
miR-210 in hypoxic response
Tumor cells can promote angiogenesis by inducing VEGF induction in stroma [151] . Interestingly, exosomes from mouse breast cancer 4T1 cells transfected with miR-210 can significantly enhance the migration and capillary formation of HUVECs [127] , suggesting that miR-210 may be one of the factors secreted by the tumor cells to promote angiogenesis. This also provides a plausible function for the increased miR-210 detected in the circulation of cancer patients [98, 99] .
miR-210 represses DNA damage response Cellular responses to DNA damage involve complex mechanisms that detect and repair genomic lesions. miRNAs have been shown to be involved in these processes [152, 153] . Recent data demonstrated that miR-210 targets RAD52 [76, 122] , a key gene in the homologous recombination (HR)-mediated repair of double-stranded breaks by assisting the loading of RAD51 onto DNA [154, 155] . As it is well established that HR repair activity is compromised in hypoxic cells [156] , miR-210-mediated suppression of RAD52 provides a novel mechanism by which HR repair is suppressed under low oxygen tensions. miR-210's role in repressing cellular DNA damage response is further supported by a recent study in which the expression of miR-210 leads to doublestranded DNA breaks in cultured fibroblasts [157] .
miR-210 regulation of apoptosis Programmed cell death, also termed apoptosis, is essential for tissue homeostasis in multicellular organisms. HIF1a plays a well-established role in regulating apoptotic pathways under hypoxia [158] . Evasion of apoptotic responses is one of the hallmarks of cancer cells [159] . Thus, it is not surprising that miR-210, the most consistently induced miRNA in hypoxic microenvironments, is implicated in regulating this critical process. Most of the evidence supports an anti-apoptotic property of miR-210: expression of miR-210 can protect cells from apoptosis [66, 75, 160, 161] , while downregulation of miR-210 leads to apoptosis [66, 68, [123] [124] [125] 162] .
Several targets have been identified as mediating miR-210's anti-apoptotic function in various experimental systems. These include E2F3 [162] , Ptp1b [126] , caspase-8-associated protein-2 (CASP8AP2) [75] , and apoptosis-inducing factor, mitochondrion-associated, 3 (AIFM3) [125] . However, among all these targets, only CASP8AP2 has been verified in independent studies [163] . In one report, although AIFM3 was found to be a miR-210 target, the overexpression of AIFM3 failed to overcome the cytoprotective effects of miR-210, suggesting that it may actually be irrelevant to miR-210's antiapoptotic function [161] .
Despite strong evidence suggesting an anti-apoptotic function of miR-210, a recent report suggested that miR-210 may have a pro-apoptotic function through targeting the antiapoptotic protein BCL2 to mediate hypoxia-induced apoptosis in neuroblastoma cells [164] . However, this result is challenged by the data from pheochromocytoma cells, where overexpressing miR-210 suppressed apoptosis with concurrently increased BCL2 levels [165] .
In summary, the anti-apoptotic function of miR-210 seems to be consistently detected in a variety of cells of different genetic backgrounds, suggesting the likelihood of its being a general mechanism. However, the relevance to cell death under hypoxic conditions in human cancers and the mechanism of miR-210-mediated anti-apoptotic function remain largely elusive.
miR-210 regulates mitochondrial metabolism
When oxygen supply is plentiful, oxidative phosphorylation (OXPHOS) is the major pathway by which cells generate ATP. However, when oxygen supply is limited, cells switch to the glycolysis. HIF1a is arguably the most important factor facilitating the transition from OXPHOS to glycolysis by upregulating glycolytic enzymes and downregulating mitochondrial respiration [85, 166] . Again, accumulating evidence suggests that miR-210 is a significant contributor to this metabolic shift by downregulating mitochondrial electron transport chain (ETC) activity.
Major targets of miR-210 mediating this effect are the iron-sulfur (Fe-S) cluster scaffold proteins, ISCU1 and ISCU2 [113, 115, 122, 131] . ISCU is the part of an ancient machinery that facilitates the assembly of Fe-S clusters that are then incorporated into enzymes that function in the TCA cycle, such as aconitase, as well as mitochondrial ETC complexes I, II, and III [167] . Moreover, the role of ISCU as a metabolic regulator has been well established, as its mutations are associated with hereditary lactic acidosis, characterized by myopathy and exercise intolerance [168] . More importantly, the expression levels of ISCU are negatively correlated with miR-210 in various tumor datasets [131] , further supporting ISCU as a biologically and pathologically relevant miR-210 target.
Several additional mitochondrial ETC components have also been reported to be miR-210 targets with varying degrees of experimental support. These include NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4 (NDUFA4) [69] , succinate dehydrogenase complex, subunit D (SDHD) [118] , and cytochrome c oxidase assembly homolog 10 (COX10) [113, 132] . NDUFA4 was thought to be a subunit of ETC Complex I until recent work demonstrating that it is actually part of Complex IV [169] . SDHD is a subunit of Complex II and is also a tumor suppressor [170, 171] . Cytochrome c oxidase (COX), also called mitochondrial ETC Complex IV, catalyzes the electron transfer from reduced cytochrome c to oxygen. COX10 encodes heme A:farnesyltransferase, which is not a structural subunit of COX but is required for the expression of functional COX [172] . By targeting multiple components of the miR-210 in hypoxic response mitochondrial ETC, robust induction of miR-210 under hypoxic conditions is an efficient way to attenuate mitochondrial respiration.
In addition to the ETC components, another intriguing miR-210 target with mitochondria-related function is the glycerol-3-phosphate dehydrogenase 1-like (GPD1L) gene [133] , which may be involved in the Pasteur effect by modulating NAD þ /NADH ratios [173] . Although the biochemical function of GPD1L remains to be elucidated, it is highly homologous to glycerol-3-phosphate dehydrogenase (GPD), the catalyst of the glycerol phosphate shuttle, which transfers electrons from cytoplasmic NADH to the mitochondrial ETC [174] . Suppression of GPD1L by miR-210 contributes to inactivation of the HIF prolyl hydroxylase activity, resulting in increased HIF1a expression [133] . An independent study also demonstrated that a high miR-210 level contributes to the maintenance of stabilized HIF1a during hypoxia [118] , suggesting that miR-210 and HIF1a may form a feed-forward loop to promote glycolysis while inhibiting mitochondrial OXPHOS activity when oxygen is limited. Collectively, these data indicate that miR-210 may be a master regulator of mitochondrial respiration in the HIF1a pathway.
It is well-known that tumors rely on glycolysis even when a sufficient oxygen supply is available, a phenomenon termed 'the Warburg effect' [175] , in which HIF1a plays an important role [8] . Interestingly, the expression of miR-210 is elevated in many cancers, including glioblastoma [176] , melanoma [77, 177] , clear cell renal cell carcinoma [95, 97] , lung [178, 179] , pancreatic [146] , and breast cancer [67, 88] . Given the potential feed-forward mechanism between HIF1a and miR-210, it is tempting to speculate that elevated miR-210 may contribute to the Warburg effect in these tumors by helping to stabilize HIF1a to promote aerobic glycolysis.
miR-210 as a potential cancer therapeutic target
The status of miR-210 expression in tumors may have therapeutic implications. Since increased expression of miR-210 is generally linked to an adverse prognosis in soft-tissue sarcoma, pediatric osteosarcoma, breast, head, and neck, and pancreatic tumors [64, 67, 146, 180, 181] . This may be exploited to sensitize these tumors to agents targeting the miR-210 pathway that the tumors may depend on. In support of this concept, it has been shown that targeting miR-210 sensitizes tumor cells to radiation in a variety of cancers [125, 182, 183] , inhibits the migration and invasion of renal cell carcinoma cells [96] , and leads to enhanced cell death [123] . Thus, we speculate that targeting miR-210 would compromise the 'fitness' of tumor cells with high-level miR-210 expression, especially those residing in a severely hypoxic microenvironment that is distant from tumor vasculature. When combined with conventional cytotoxic agents that usually eliminate well-oxygenated tumor cells, this may create a new avenue for more effective cancer treatment.
Concluding Remarks
From the experimental evidence we have discussed above, it is clear that miR-210 plays a critical role in the cellular response to hypoxia and in cancer biology, especially in the context of tumor hypoxia. Given the robust induction of miR-210 under hypoxic conditions in cells from disparate genetic backgrounds and the versatility of functions it possesses, establishing a simple and general mechanistic model of miR-210 function is unlikely. New experimental approaches and animal models are anticipated to address many of the outstanding questions. Finally, it is clear that manipulating miR-210 expression alters cellular homeostasis, and can result in either tumor growth inhibition or tumor cell apoptosis, depending on the cellular context. Therefore, a major challenge for the future is to more accurately define the contextual effects of miR-210 inhibition in normal tissues and tumors so that the potential of therapeutically targeting miR-210 can be explored.
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